On July 13, WuXi XDC (02268.HK) declined 3.23% in regular trading to HK$58.05, with turnover of HK$97.16 million. The pullback follows a multi-day rally last week fueled by concentrated positive analyst coverage—CLSA raised its target price to HK$82.6 maintaining an \"Outperform\" rating, while Daiwa initiated with a \"Buy\" rating and HK$78 target, naming the company a top CXO pick. The stock had reached an intraday high of HK$62.40 on July 10.

However, southbound funds have been net sellers in recent sessions, reducing holdings by 2.54 million shares on July 9 and 1.00 million shares on July 10, signaling institutional profit-taking. Morgan Stanley had also lowered its target price from HK$83 to HK$80 on July 6, cutting earnings forecasts for the next several years citing lower gross margins from the Topharma consolidation and forex headwinds.

Within the Life Sciences Tools & Services sector, WuXi Biologics fell 1.42% and WuXi AppTec declined 0.9%, while Genscript Bio rose 3.76% and JOINN gained 3.84%, reflecting divergent performance among peers.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)